In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells.

Abstract

OBJECTIVES:

Autoreactive B cells play a crucial role in the pathogenesis of rheumatoid arthritis (RA), and B cell-depleting therapies using an antibodies, such as rituximab, have been suggested to be effective in RA treatment. However, transient B cell depletion with rituximab is associated with significant safety challenges related to global suppression of the immune system and thus increases the risks of infection and cancer development. To address selective and persistent issues associated with RA therapy, we developed a customised therapeutic strategy employing universal antifluorescein isothiocyanate (FITC) chimeric antigen receptor T cells (CAR-T cells) combined with FITC-labelled antigenic peptide epitopes to eliminate autoreactive B cell subsets recognising these antigens in RA.

METHODS:

For a proof-of-concept study, four citrullinated peptide epitopes derived from citrullinated autoantigens, namely, citrullinated vimentin, citrullinated type II collagen, citrullinated fibrinogen and tenascin-C, and a cyclocitrulline peptide-1 were selected as ligands for targeting autoreactive B cells; Engineered T cells expressing a fixed anti-FITC CAR were constructed and applied as a universal CAR-T cell system to specifically eliminate these protein-specific autoreactive B cells via recognition of the aforementioned FITC-labelled autoantigenic peptide epitopes.

RESULTS:

We demonstrated that anti-FITC CAR-T cells could be specifically redirected and kill hybridoma cells generated by immunisation with antigenic peptides, and autoreactive B cell subsets from RA patients via recognition of corresponding FITC-labelled citrullinated peptide epitopes. Additionally, the cytotoxicity of the CAR-T cells was dependent on the presence of the peptides and occurred in a dose-dependent manner.

CONCLUSIONS:

The approach described here provides a direction for precise, customised approaches to treat RA and can likely be applied to other systemic autoimmune diseases.

• Authors: Bo Zhang, Yan Wang, Yeshuang Yuan, Jiaqi Sun, Lulu Liu, Dan Huang, Jin Hu, Min Wang, Shengjie Li, Wei Song, Hua Chen, Demin Zhou, Xuan Zhang
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 80 Issue 2 Pg. 176-184 (02 2021) ISSN: 1468-2060 [Electronic] England
• PMID: 32998865 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Autoantigens
• Collagen Type II
• Epitopes
• Ligands
• Peptides, Cyclic
• Receptors, Antigen, T-Cell
• Receptors, Chimeric Antigen
• Tenascin
• Vimentin
• cyclic citrullinated peptide
• Fibrinogen
• Fluorescein-5-isothiocyanate

Topics

• Adult
• Antigen-Presenting Cells (immunology)
• Arthritis, Rheumatoid (immunology, therapy)
• Autoantigens (immunology)
• B-Lymphocytes (immunology)
• Collagen Type II (immunology)
• Epitopes (immunology)
• Female
• Fibrinogen (immunology)
• Fluorescein-5-isothiocyanate (therapeutic use)
• Humans
• Immunotherapy, Adoptive (methods)
• Ligands
• Male
• Peptides, Cyclic (immunology)
• Proof of Concept Study
• Receptors, Antigen, T-Cell (therapeutic use)
• Receptors, Chimeric Antigen (therapeutic use)
• Tenascin (immunology)
• Vimentin (immunology)